Vector applied for registration of another COVID-19 vaccine

The Novosibirsk center Vector, which developed the EpiVacCorona CORONAVIRUS vaccine, has submitted documents to the Ministry of HEALTH for registration of another drug, follows from the data of the state register of medicines.

The drug was named "EpiVacCorona-N", it was developed using peptide antigens. The same technology was used to create the first vaccine.

The Ministry of Health issued permission to test a new vaccine in April.